UTHealth Houston at ObesityWeek 2026
Nov 14–17, 2026 National Harbor, MD ~4.4k attendees Website
UTHealth Houston brings 12 presentations to ObesityWeek 2026 in National Harbor. Its program centers on newer obesity drugs, from amylin analogues and CagriSema doses in REDEFINE 9 to switching from injections to oral treatment. Other work uses proteomics and integrative omics to explain how semaglutide works and what drives its gastrointestinal side effects.
| Organization | ObesityWeek 2026 Attendance |
|---|---|
UTHealth Houston Houston, TX | |
UT System health sciences university in the Texas Medical Center. | Talk Sun Nov 15 7:30am–8:30am Weight Management Foundayo Peer-led review of dosing, efficacy and safety for a once-daily oral obesity medicine for adults, with time for audience questions. Metabolism and integrative physiologyPopulation health and epidemiologyNutrition, diet and food Talk Sun Nov 15 11:45am–1:15pm Treating Obesity First: Exploring the Role of Amylin Analogues in the Future of Obesity Care Reviews trial data on amylin analogues, which act through a different hormone pathway than GLP-1, as single or combination obesity treatments. Interventional and clinical studiesNutrition, diet and food Poster Sun Nov 15 2:30pm–3:30pm Characterizing Circulating Proteomic Markers of GLP-1RAs Associated with Gastrointestinal Side Effects Obesity pharmacotherapy and drug developmentClinical obesity care and professional practice Poster Sun Nov 15 2:30pm–3:30pm REDEFINE 9: Effect of CagriSema 1.7 mg/1.7 mg and 1.0 mg/1.0 mg in Adults with Overweight or Obesity Metabolism and integrative physiology Session Sun Nov 15 5:00pm–6:30pm Talk Sun Nov 15 5:40pm–6:00pm Talk Sun Nov 15 6:30pm–9:00pm Obesity in Focus: Today's Evidence. Tomorrow's Possibilities. Speakers cover what has changed in obesity guidelines, evidence behind approved obesity drugs, and the biology of amylin and new amylin analog data. Interventional and clinical studiesClinical obesity care and professional practiceNutrition, diet and foodObesity pharmacotherapy and drug development Talk Mon Nov 16 10:45am–11:00am Session Mon Nov 16 1:30pm–2:30pm Beyond the Injection: Navigating the Switch to Oral Obesity Treatment Options Covers when and why to move patients from injected to newer oral obesity drugs, and practical steps for managing the switch. Clinical obesity care and professional practiceObesity pharmacotherapy and drug development Poster Mon Nov 16 2:30pm–3:30pm Risks of Developing Metabolic and Cardiorenal Complications Across BMI Categories Policy and public health Poster Mon Nov 16 2:30pm–3:30pm Session Tue Nov 17 10:00am–11:00am Merging Modalities: A Unified Approach to Treating the Patient with BMI >35 Covers why many people with severe obesity miss effective treatment and how to order drugs, metabolic surgery and other options for each patient. Clinical obesity care and professional practiceBariatric surgery and devicesObesity pharmacotherapy and drug development |
Find decision makers at UTHealth Houston
Tell us what you sell and we’ll find the people at UTHealth Houston most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by The Obesity Society (TOS), ObesityWeek® or the American Society for Metabolic and Bariatric Surgery (ASMBS). Submit a correction